London close: Stocks mixed on corporate updates, trade developments
29th Jul 2025 16:28
(Sharecast News) - London stocks ended Tuesday on a mixed note as a wave of corporate results kept investors busy and market participants continued to assess the implications of the recent US-EU trade deal.
Read moreAstrazeneca H1 gross profits up 10pc as 'strong growth momentum' continues
29th Jul 2025 07:09
(Sharecast News) - Drugmaker Astrazeneca said on Tuesday that "strong growth momentum" had continued in H1, with "excellent R&D pipeline delivery" in the year-to-date.
Read moreLondon close: Stocks reverse gains to finish lower
28th Jul 2025 17:16
(Sharecast News) - London stocks ended lower on Monday, erasing earlier gains as investors reassessed the weekend's trade agreement between the United States and the European Union.
Read moreAstraZeneca reports positive results from autoimmune treatment trial
24th Jul 2025 08:27
(Sharecast News) - AstraZeneca announced on Thursday that its investigational treatment 'gefurulimab' achieved statistically significant and clinically meaningful results in a phase three trial for generalised myasthenia gravis (gMG), a rare autoimmune neuromuscular disorder.
Read moreAstraZeneca to invest $50bn in US manufacturing and R&D
22nd Jul 2025 07:06
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that it plans to invest $50.0bn in the US for medicines manufacturing and R&D by 2030.
Read moreLondon close: Stocks fall after rise in UK consumer inflation
16th Jul 2025 17:49
(Sharecast News) - London equities slipped on Wednesday as stronger-than-expected UK inflation data offset a decline in US producer inflation, prompting investor caution over the interest rate outlook.
Read moreAstraZeneca drug fails to meet main goal in late-stage amyloidosis trial
16th Jul 2025 07:31
(Sharecast News) - An investigational AstraZeneca treatment for amyloidosis has failed to show a statistical significance in late-stage trials, the blue chip pharmaceutical group said on Wednesday.
Read moreLondon close: Stocks rise despite renewed trade tensions
14th Jul 2025 17:45
(Sharecast News) - London stocks closed higher on Monday, buoyed by geopolitical trade developments after US president Donald Trump announced plans to impose 30% tariffs on imports from the European Union and Mexico.
Read moreBerenberg raises target price on AstraZeneca
9th Jul 2025 09:01
(Sharecast News) - Analysts at Berenberg raised their target price on drugmaker AstraZeneca from £140 to £142 per share on Wednesday, citing "strong pipeline readouts" which were yet to be reflected in its share price.
Read moreSunday newspaper round-up: Trade, AstraZeneca, Tax hikes
6th Jul 2025 12:41
(Sharecast News) - Brussels is heading into a critical week, with just two to go to clinch a trade agreement with the US or face a 50% levy on its exports. At stake are €1.6trn in transatlantic trade. Germany is down as favouring a quick deal akin to that inked by the UK so as to avoid a full-blown trade war. Paris on the other hand believes that the EU should hold out if too quick a deal is "imbalanced" - Guardian
Read moreLondon close: FTSE finishes flat ahead of Trump tariff deadline
4th Jul 2025 17:48
(Sharecast News) - London stocks ended Thursday little changed at the top tier but weaker further down the board, as investors weighed fresh economic data and cautious sentiment ahead of Donald Trump's 9 July tariff deadline next week.
Read moreAstraZeneca's Imfinzi gets EU green light
4th Jul 2025 07:10
(Sharecast News) - Drugmaker AstraZeneca said on Friday that its Imfinzi asset has been approved in the EU as the first and only perioperative immunotherapy for muscle-invasive bladder cancer.
Read moreAstraZeneca's Datroway gets green light from FDA
24th Jun 2025 07:10
(Sharecast News) - Drugmaker AstraZeneca's Datroway has been approved in the US for adult patients with previously treated advanced EGFR-mutated non-small cell lung cancer.
Read moreAstraZeneca launches strategic research collaboration with China's CSPC Pharmaceuticals
13th Jun 2025 09:51
(Sharecast News) - Drugmaker AstraZeneca revealed on Friday that it has entered a strategic research collaboration with Chinese firm CSPC Pharmaceuticals Group.
Read moreAstraZeneca's Calquence receives European Commission approval
6th Jun 2025 08:05
(Sharecast News) - Drugmaker AstraZeneca said on Friday that it had received approval from the European Commission for fixed-duration regimens of its chronic lymphocytic leukaemia candidate Calquence in a first-line setting.
Read more